Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 14, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,403.66 pence per share.
- Treasury Holdings: 263,172,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,746,368,189 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 1,400,000 shares on March 14, 2007. The filing does not provide comparative financial data against prior periods to assess changes in operational performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (263,172,678) against subsequent filings.
- Confirm the total voting rights denominator (5,746,368,189) for disclosure threshold calculations under FSA rules.
- Review the Annual General Meeting minutes from May 17, 2006, to confirm the scope of the share repurchase authority.